Geriatric Rheumatology (Thai)
Article Sidebar
Main Article Content
Abstract
การเปลี่ยนแปลงของร่างกายเมื่อมีอายุมากขึ้นเป็นกระบวนการทางชีวภาพที่ซับซ้อน มีลักษณะจำเพาะ คือ การทำงานของเซลล์ลดลง ทำให้เสียสภาวะสมดุลของร่างกาย และก่อให้เกิดโรคในผู้สูงอายุ ได้แก่ โรคจากความเสื่อมของระบบประสาท โรคมะเร็ง โรคหัวใจและหลอดเลือด รวมไปถึงโรคข้อและแพ้ภูมิตนเอง การเปลี่ยนแปลงนี้ส่งผลต่อคุณภาพชีวิต และอาจทำให้เสียชีวิต1 ในปัจจุบันผู้สูงอายุมีจำนวนมากขึ้น2 ลักษณะทางคลินิกของโรคข้อและแพ้ภูมิตนเองและแนวทางการรักษาในผู้สูงอายุมีความแตกต่างจากผู้ป่วยทั่วไป บทความนี้กล่าวถึงกระบวนการชราภาพ การเปลี่ยนแปลงของระบบภูมิคุ้มกัน และกลุ่มโรคแพ้ภูมิตนเองที่พบบ่อยในผู้สูงอายุ
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
References
Alsaleh G, Richter FC, Simon AK. Age-related mechanisms in the context of rheumatic disease. Nat Rev Rheumatol. 2022;18(12):694-710.
nations u. World Population Ageing 2019. World Population Ageing 2019.
Lian J, Yue Y, Yu W, Zhang Y. Immunosenescence: a key player in cancer development. J Hematol Oncol. 2020;13(1):151.
Solana R, Campos C, Pera A, Tarazona R. Shaping of NK cell subsets by aging. Curr Opin Immunol. 2014;29:56-61.
Mongkolchaiarunya J, Wongthanee A, Kasitanon N, Louthrenoo W. Comparison of clinical features, disease activity, treatment and outcomes between late-onset and early-onset patients with systemic lupus erythematosus. A sex- and year at diagnosis-matched controlled study. Advances in Rheumatology. 2023;63(1):20.
Wen L, Chen Z, Jin Z, Pan W, Liu L, Wu M, et al. Clinical and laboratorial outcome of different age-onset systemic lupus erythematosus patients in Jiangsu, China: a multicentre retrospective study. Scientific Reports. 2022;12(1):10683.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29.
Manzo C, Gareri P, Castagna A. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Safety - Case Reports. 2017;4(1):6.
Liddle GW. EFFECTS OF ANTI-INFLAMMATORY STEROIDS ON ELECTROLYTE METABOLISM. Annals of the New York Academy of Sciences. 1959;82(4):854-67.
Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016;76(4):459-83.
Staub HL, Franck M, Ranzolin A, Norman GL, Iverson GM, von Mühlen CA. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev. 2006;6(2):104-6.
Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun Rev. 2020;19(6):102528.
Chalan P, van den Berg A, Kroesen BJ, Brouwer L, Boots A. Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging. Curr Aging Sci. 2015;8(2):131-46.
Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ. Proinflammatory Cytokine Profiles of Patients with Elderly-Onset Rheumatoid Arthritis: A Comparison with Younger-Onset Disease. Gerontology. 2009;55(3):250-8.
Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55(5):780-91.
Chen YM, Chen LK, Lan JL, Chen DY. Geriatric syndromes in elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(10):1261-4.
Ranganath VK, Maranian P, Elashoff DA, Woodworth T, Khanna D, Hahn T, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;52(10):1809-17.
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212.
Ruban TN, Jacob B, Pope JE, Keystone EC, Bombardier C, Kuriya B. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. Clin Rheumatol. 2016;35(3):759-63.
Wang D, Zhang J, Lau J, Wang S, Taneja V, Matteson EL, et al. Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(10):581-96.
Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415-21.
Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W, et al. Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatol Int. 2020;40(12):1987-95.
Díaz-Borjón A. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging. 2009;26(4):273-93.
Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914-20.
Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. Rheumatology (Oxford). 2016;55(5):874-82.
Payet S, Soubrier M, Perrodeau E, Bardin T, Cantagrel A, Combe B, et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res (Hoboken). 2014;66(9):1289-95.
Curtis JR, Schulze-Koops H, Takiya L, Mebus CA, Terry KK, Biswas P, et al. Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017;35(3):390-400.
Fleischmann R, Alam J, Arora V, Bradley J, Schlichting DE, Muram D, et al. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 2017;3(2):e000546.
Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis. 2015;74(6):1065-71.
Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015;74(7):1360-7.
van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020;180(10):1295-304.
Muller G, Devilliers H, Besancenot JF, Manckoundia P. Giant cell arteritis (Horton's disease) in very elderly patients aged 80 years and older: A study of 25 cases. Geriatr Gerontol Int. 2016;16(6):679-85.
Hazzard's geriatric medicine and gerontology Jeffrey B Halter Hazzard's geriatric medicine and gerontology et al McGraw-Hill Medical £154.99 1760pp 9780071488723 [Formula: see text]. Nurs Older People. 2010;22(6):10.
Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. J Rheumatol. 2016;43(6):1085-92.
García-Carrasco M, Cervera R, Rosas J, Ramos-Casals M, Morlà RM, Sisó A, et al. Primary Sjögren's syndrome in the elderly: clinical and immunological characteristics. Lupus. 1999;8(1):20-3.
García-Carrasco M, Ramos-Casals M, Rosas J, Pallarés L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270-80.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3-18.
Manzo C, Kechida M. Is primary Sjögren's syndrome a risk factor for malignancies different from lymphomas? What does the literature highlight about it? Reumatologia. 2017;55(3):136-9.
Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636-46.
Barone M, Viggiani MT, Anelli MG, Fanizzi R, Lorusso O, Lopalco G, et al. Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. J Clin Med. 2018;7(12).
Valido A, Crespo CL, Pimentel-Santos FM. Muscle Evaluation in Axial Spondyloarthritis-The Evidence for Sarcopenia. Front Med (Lausanne). 2019;6:219.
Hasegawa E, Ito S, Kurosawa Y, Kobayashi D, Otani H, Abe A, et al. The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis. Intern Med. 2023;62(3):373-9.
Ganapathy A, Nieves JW. Nutrition and Sarcopenia-What Do We Know? Nutrients. 2020;12(6).
Prado CM, Orsso CE, Pereira SL, Atherton PJ, Deutz NEP. Effects of β-hydroxy β-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review. J Cachexia Sarcopenia Muscle. 2022;13(3):1623-41.